ArticleFrontiers in pediatrics2026
Opioid and benzodiazepine requirements in neonatal and pediatric patients undergoing venoarterial ECMO: insights from a predominantly cardiac cohort.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Managing sedation and analgesia in neonates and pediatric patients supported with extracorporeal membrane oxygenation (ECMO) is challenging due to altered pharmacokinetics, prolonged critical illness, and the need for deep sedation to maintain circuit integrity. Limited data describing cumulative opioid and benzodiazepine exposure and factors associated with dose escalation in pediatric ECMO populations. Methods: We conducted a retrospective cohort study of neonates and pediatric patients aged ≤14 years who received ≥72 h of venoarterial ECMO support in a pediatric cardiac surgical intensive care unit between 2019 and 2023. Exclusions included early mortality, neurological conditions requiring altered sedation strategies, or sedation primarily used for seizure management. Opioid and benzodiazepine doses administered during ECMO were converted to intravenous morphine and midazolam equivalents. Cumulative (mg/kg) and average daily (mg/kg/day) exposures were calculated. Multivariable regression analyses were performed to identify clinical predictors of sedative and analgesic dose requirements and associations with outcomes. Results: Eighty patients were included, with postoperative cardiac disease accounting for 68.8% of primary diagnoses. All patients received opioids, and 96.3% received benzodiazepines; 66.3% received adjunctive sedative agents. Median cumulative opioid and benzodiazepine exposures were 7.33 mg/kg and 15.75 mg/kg, respectively. Prolonged ICU length of stay and ECMO duration were independently associated with higher cumulative opioid exposure (Coeff = 0.02; 95% CI: 0.01 to 0.03; Conclusion: Prolonged ICU stays and ECMO courses in neonatal and pediatric patients significantly increase cumulative opioid burdens. Crucially, higher average opioid doses, acute kidney injury, and extended ICU and ECMO durations serve as key clinical predictors of increased in-hospital mortality. These findings highlight the need for individualized, physiology-informed sedation strategies and structured weaning approaches to optimize outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.